HCV Protease

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1482 Daclatasvir (BMS-790052) <1 mg/mL 148 mg/mL 148 mg/mL
S1538 Telaprevir (VX-950) <1 mg/mL 136 mg/mL <1 mg/mL
S1480 Lomibuvir (VX-222, VCH-222) <1 mg/mL 89 mg/mL 89 mg/mL
S1183 Danoprevir (ITMN-191) <1 mg/mL 144 mg/mL 144 mg/mL
S4935 Asunaprevir <1 mg/mL 100 mg/mL 100 mg/mL
S5720 Glecaprevir -1 mg/mL 100 mg/mL -1 mg/mL
S5652 Elbasvir <1 mg/mL 100 mg/mL 100 mg/mL
S5394 Tizoxanide <1 mg/mL 27 mg/mL <1 mg/mL
S5402 Dasabuvir(ABT-333) <1 mg/mL 98 mg/mL <1 mg/mL
S5404 Paritaprevir (ABT-450) -1 mg/mL 100 mg/mL -1 mg/mL
S5403 Ombitasvir (ABT-267) -1 mg/mL 100 mg/mL -1 mg/mL
S5307 PSI-6206 (RO-2433, GS-331007) 52 mg/mL 52 mg/mL 24 mg/mL
S5062 Daclatasvir Dihydrochloride 100 mg/mL 100 mg/mL 100 mg/mL
S5015 Simeprevir <1 mg/mL 100 mg/mL 4 mg/mL
S3728 Grazoprevir <1 mg/mL 100 mg/mL 100 mg/mL
S7579 Ledipasvir (GS5885) <1 mg/mL 100 mg/mL 100 mg/mL
S3800 Lycorine hydrochloride -1 mg/mL 64 mg/mL -1 mg/mL
S3724 Velpatasvir 100 mg/mL 100 mg/mL 100 mg/mL
S3733 Boceprevir <1 mg/mL 100 mg/mL 100 mg/mL
Catalog No. Information Product Use Citations Product Validations

Daclatasvir (BMS-790052)

Daclatasvir (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.


Telaprevir (VX-950)

Telaprevir (VX-950) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.


Lomibuvir (VX-222, VCH-222)

Lomibuvir (VX-222, VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2.


Danoprevir (ITMN-191)

Danoprevir(ITMN-191) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.



Asunaprevir is an orally bioavailable inhibitor of the hepatitis C virus enzyme serine protease NS3 that is necessary for protein processing required for viral replication.



Glecaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that targets the the viral RNA replication. It displays IC50 values ranging from 3.5 to 11.3 nM for clinical isolates of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a.



Elbasvir is an NS5A inhibitor, preventing hepatitis C viral RNA replication and virion assembly. Median EC50 values range from 0.2 to 3600 pmol/L, based on genotype.



Tizoxanide, a thiazolide anti-infective, is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical development for treating chronic hepatitis C.



Dasabuvir(ABT-333) is a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase that inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates with IC50 values between 2.2 and 10.7 nM. It is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases.


Paritaprevir (ABT-450)

Paritaprevir (ABT-450) is a nonstructural (NS) protein 3/4A protease inhibitor.


Ombitasvir (ABT-267)

Ombitasvir (ABT-267) is an inhibitor of the HCV non-structural protein 5A with antiviral activity.


PSI-6206 (RO-2433, GS-331007)

PSI-6206 (RO-2433, GS-331007) is a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase, targeting NS5B polymerase.


Daclatasvir Dihydrochloride

Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.



Simeprevir is a competitive, reversible, macrocyclic, noncovalent hepatitis C virus (HCV) NS3/4A protease inhibitor that acts directly against the hepatitis C virus. It has a medium inhibitory concentration (IC50) <13 nM for all HCV NS3/4A enzymes(genotypes 1a, 1b, 2, 4, 5, and 6), but has an IC50 value of 37 nM for genotype 3.



Grazoprevir anhydrous is a Hepatitis C Virus NS3/4A Protease inhibitor with IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively.


Ledipasvir (GS5885)

Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.


Lycorine hydrochloride

Lycorine, a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit a wide range of physiological effects, including the potential effect against cancer. It is an HCV inhibitor with strong activity.



Velpatasvir is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.



Boceprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.

Tags: HCV protease treatment | HCV protease assay | HCV protease inhibitors review